Cargando…
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914155/ https://www.ncbi.nlm.nih.gov/pubmed/35309859 http://dx.doi.org/10.1002/jbm4.10600 |
_version_ | 1784667642724876288 |
---|---|
author | Damrath, John G Chen, Neal X Metzger, Corinne E Srinivasan, Shruthi O'Neill, Kalisha Biruete, Annabel Avin, Keith G Wallace, Joseph M Allen, Matthew R Moe, Sharon M |
author_facet | Damrath, John G Chen, Neal X Metzger, Corinne E Srinivasan, Shruthi O'Neill, Kalisha Biruete, Annabel Avin, Keith G Wallace, Joseph M Allen, Matthew R Moe, Sharon M |
author_sort | Damrath, John G |
collection | PubMed |
description | Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen species formation and reduce parathyroid hormone (PTH) levels would have additive beneficial effects to prevent cardiovascular calcification and deleterious bone architecture and mechanics before end‐stage kidney disease. To test this hypothesis, we treated a naturally progressive model of CKD‐MBD, the Cy/+ rat, beginning early in CKD with the NADPH oxidase (NOX1/4) inhibitor GKT‐137831 (GKT), the preclinical analogue of the calcimimetic etelcalcetide, KP‐2326 (KP), and their combination. The results demonstrated that CKD animals had elevated blood urea nitrogen, PTH, fibroblast growth factor 23 (FGF23), and phosphorus. Treatment with KP reduced PTH levels compared with CKD animals, whereas GKT treatment increased C‐terminal FGF23 levels without altering intact FGF23. GKT treatment alone reduced aortic calcification and NOX4 expression but did not alter the oxidative stress marker 8‐OHdG in the serum or aorta. KP treatment reduced aortic 8‐OHdG and inhibited the ability for GKT to reduce aortic calcification. Treatments did not alter heart calcification or left ventricular mass. In the skeleton, CKD animals had reduced trabecular bone volume fraction and trabecular number with increased trabecular spacing that were not improved with either treatment. The cortical bone was not altered by CKD or by treatments at this early stage of CKD. These results suggest that GKT reduces aortic calcification while KP reduces aortic oxidative stress and reduces PTH, but the combination was not additive. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. |
format | Online Article Text |
id | pubmed-8914155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89141552022-03-18 Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) Damrath, John G Chen, Neal X Metzger, Corinne E Srinivasan, Shruthi O'Neill, Kalisha Biruete, Annabel Avin, Keith G Wallace, Joseph M Allen, Matthew R Moe, Sharon M JBMR Plus Original Article Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen species formation and reduce parathyroid hormone (PTH) levels would have additive beneficial effects to prevent cardiovascular calcification and deleterious bone architecture and mechanics before end‐stage kidney disease. To test this hypothesis, we treated a naturally progressive model of CKD‐MBD, the Cy/+ rat, beginning early in CKD with the NADPH oxidase (NOX1/4) inhibitor GKT‐137831 (GKT), the preclinical analogue of the calcimimetic etelcalcetide, KP‐2326 (KP), and their combination. The results demonstrated that CKD animals had elevated blood urea nitrogen, PTH, fibroblast growth factor 23 (FGF23), and phosphorus. Treatment with KP reduced PTH levels compared with CKD animals, whereas GKT treatment increased C‐terminal FGF23 levels without altering intact FGF23. GKT treatment alone reduced aortic calcification and NOX4 expression but did not alter the oxidative stress marker 8‐OHdG in the serum or aorta. KP treatment reduced aortic 8‐OHdG and inhibited the ability for GKT to reduce aortic calcification. Treatments did not alter heart calcification or left ventricular mass. In the skeleton, CKD animals had reduced trabecular bone volume fraction and trabecular number with increased trabecular spacing that were not improved with either treatment. The cortical bone was not altered by CKD or by treatments at this early stage of CKD. These results suggest that GKT reduces aortic calcification while KP reduces aortic oxidative stress and reduces PTH, but the combination was not additive. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2022-02-11 /pmc/articles/PMC8914155/ /pubmed/35309859 http://dx.doi.org/10.1002/jbm4.10600 Text en © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Damrath, John G Chen, Neal X Metzger, Corinne E Srinivasan, Shruthi O'Neill, Kalisha Biruete, Annabel Avin, Keith G Wallace, Joseph M Allen, Matthew R Moe, Sharon M Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title |
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title_full |
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title_fullStr |
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title_full_unstemmed |
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title_short |
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) |
title_sort | non‐additive effects of combined nox1/4 inhibition and calcimimetic treatment on a rat model of chronic kidney disease‐mineral and bone disorder (ckd‐mbd) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914155/ https://www.ncbi.nlm.nih.gov/pubmed/35309859 http://dx.doi.org/10.1002/jbm4.10600 |
work_keys_str_mv | AT damrathjohng nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT chennealx nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT metzgercorinnee nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT srinivasanshruthi nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT oneillkalisha nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT birueteannabel nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT avinkeithg nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT wallacejosephm nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT allenmatthewr nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd AT moesharonm nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd |